BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 35795830)

  • 1. Severe and delayed-onset acneiform eruptions as an adverse reaction to regorafenib.
    Otsuka H; Fukumoto T; Kiyota N; Takemori C; Jimbo H; Nishigori C
    Dermatol Reports; 2022 Jun; 14(2):9303. PubMed ID: 35795830
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acneiform eruption induced by cetuximab.
    Cotena C; Gisondi P; Colato C; Girolomoni G
    Acta Dermatovenerol Croat; 2007; 15(4):246-8. PubMed ID: 18093454
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regorafenib: a novel multitargeted tyrosine kinase inhibitor for colorectal cancer and gastrointestinal stromal tumors.
    Crona DJ; Keisler MD; Walko CM
    Ann Pharmacother; 2013 Dec; 47(12):1685-96. PubMed ID: 24259629
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A case of successfully treated recalcitrant EGFR inhibitor-induced acneiform eruption following non-ablative fractional laser.
    Choi JW; Kim TI; Jeong KH; Shin MK
    Dermatol Ther; 2016 Jul; 29(4):252-4. PubMed ID: 27146102
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of epidermal growth factor receptor inhibitor-induced acneiform eruption with topical recombinant human epidermal growth factor.
    Shin JU; Park JH; Cho BC; Lee JH
    Dermatology; 2012; 225(2):135-40. PubMed ID: 23006507
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of topical benzoyl peroxide for prolonged acneiform eruptions induced by cetuximab and panitumumab: A multicenter, phase II trial.
    Tsutsui K; Kikuchi K; Nozawa K; Takashima A; Tsuchiyama K; Namikawa K; Aiba S; Yamazaki N
    J Dermatol; 2021 Jul; 48(7):1077-1080. PubMed ID: 33682955
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Histopathology of acneiform eruptions in patients treated with epidermal growth factor receptor inhibitors.
    Brodell LA; Hepper D; Lind A; Gru AA; Anadkat MJ
    J Cutan Pathol; 2013 Oct; 40(10):865-70. PubMed ID: 23941617
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The safety of regorafenib for the treatment of gastrointestinal stromal tumors.
    Rutkowski P; Stępniak J
    Expert Opin Drug Saf; 2016 Jan; 15(1):105-16. PubMed ID: 26651387
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term follow-up results of the multicenter phase II trial of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of standard tyrosine kinase inhibitor therapy.
    Ben-Ami E; Barysauskas CM; von Mehren M; Heinrich MC; Corless CL; Butrynski JE; Morgan JA; Wagner AJ; Choy E; Yap JT; Van den Abbeele AD; Solomon SM; Fletcher JA; Demetri GD; George S
    Ann Oncol; 2016 Sep; 27(9):1794-9. PubMed ID: 27371698
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A systematic review of oral retinoids for treatment of acneiform eruptions induced by epidermal growth factor receptor inhibitors.
    Bierbrier R; Lam M; Pehr K
    Dermatol Ther; 2022 May; 35(5):e15412. PubMed ID: 35220635
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial.
    Demetri GD; Reichardt P; Kang YK; Blay JY; Rutkowski P; Gelderblom H; Hohenberger P; Leahy M; von Mehren M; Joensuu H; Badalamenti G; Blackstein M; Le Cesne A; Schöffski P; Maki RG; Bauer S; Nguyen BB; Xu J; Nishida T; Chung J; Kappeler C; Kuss I; Laurent D; Casali PG;
    Lancet; 2013 Jan; 381(9863):295-302. PubMed ID: 23177515
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acneiform eruptions: a common cutaneous toxicity of the MEK inhibitor trametinib.
    Anforth R; Liu M; Nguyen B; Uribe P; Kefford R; Clements A; Long GV; Fernandez-Peñas P
    Australas J Dermatol; 2014 Nov; 55(4):250-4. PubMed ID: 24313958
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Severe EGFR inhibitor-induced acneiform eruption responding to dapsone.
    Beshay A; Petersen M; Rhoads JLW
    Dermatol Online J; 2021 Jul; 27(7):. PubMed ID: 34391331
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Acneiform eruptions induced by cetuximab].
    Walon L; Gilbeau C; Lachapelle JM
    Ann Dermatol Venereol; 2003 Apr; 130(4):443-6. PubMed ID: 12843857
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sorafenib-induced Facial Acneiform Eruption.
    Mijares MC; Aldahan AS; Gonzalez HH; Jaimes JP
    Cureus; 2019 Apr; 11(4):e4545. PubMed ID: 31275769
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Twelve cases of acneiform eruptions while on anti-CTLA4 therapy.
    Welborn M; Kubicki SL; Garg N; Patel AB
    Support Care Cancer; 2020 Jun; 28(6):2499-2502. PubMed ID: 32147760
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [A case of recurrent duodenal gastrointestinal stromal tumor resistant to imatinib and sunitinib, successfully treated with regorafenib].
    Takeda Y; Nakahira S; Katsura Y; Ohmura Y; Kusama H; Kuroda Y; Goto T; Hashimoto T; Kimura K; Matsushita K; Sato Y; Morimoto Y; Ishida T; Nitta K; Kagawa Y; Okishiro M; Takeno A; Sakisaka H; Taniguchi H; Egawa C; Ohzono K; Nakatsuka S; Kato T; Tamura S
    Gan To Kagaku Ryoho; 2014 Nov; 41(12):1545-7. PubMed ID: 25731247
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acneiform eruptions induced by epidermal growth factor receptor inhibitors: treatment with oral isotretinoin.
    Requena C; Llombart B; Sanmartín O
    Cutis; 2012 Aug; 90(2):77-80. PubMed ID: 22988651
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Malassezia folliculitis presented as acneiform eruption after cetuximab administration.
    Cholongitas E; Pipili C; Ioannidou D
    J Drugs Dermatol; 2009 Mar; 8(3):274-5. PubMed ID: 19271376
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy, tolerability and impact on quality of life of clindamycin phosphate and benzoyl peroxide for the treatment of cetuximab-associated acneiform eruption in patients with metastatic colorectal cancer.
    Vaccaro M; Guarneri F; Borgia F; Pollicino A; Altavilla G; Cannavò SP
    J Dermatolog Treat; 2016; 27(2):148-52. PubMed ID: 26313697
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.